Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction
     3.1 Classification of Gene Therapy Techniques
     3.2 Physical Methods of Gene Transfer
            3.2.1 Electroporation
            3.2.2 Hydrodynamic
            3.2.3 Microinjection
            3.2.4 Particle Bombardment
            3.2.5 Ultrasound-Mediated Transfection
     3.3 Vectors for Gene Therapy
            3.3.1 Viral Vectors
                       3.3.1.1 Adenoviral Vectors
                       3.3.1.2 Adeno-associated Virus Vectors
                       3.3.1.3 Retroviral Vectors
                       3.3.1.4 Lentiviral Vectors
            3.3.2 Non Viral Vectors
                       3.3.2.1 Naked DNA/Plasmid Vectors
                       3.3.2.2 Oligonucleotides
                       3.3.2.3 Liposomes, Lipoplexes and Polyplexes
                       3.3.2.4 Gene-Activated Matrix

4. Industry Overview
     4.1 Market Drivers
            4.1.1 Failure of Conventional Therapies to Treat Cancers
            4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
            4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
            4.1.4 Growing Interest of Venture Capital Firms
     4.2 Market Restraints
            4.2.1 Stringent Regulatory Laws & Safety Concerns
            4.2.2 Pitfalls in Current Technique
            4.2.3 High Cost of the Gene Therapy Drugs
     4.3 Market Opportunities
            4.3.1 Approval of Gene Therapy Drug in Europe
            4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
     4.4 Industry Trends
            4.4.1 Gene Silencing: Gaining Momentum
            4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
            4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
            4.4.4 Nanotechnology: Empowering Gene Therapy
            4.4.5 Gene Therapy: A New Hope to Treat Blindness
            4.4.6 Gene Therapy: Potential Cure for Cancer
     4.5 Winning Imperatives
            4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis
     5.1 Clinical Trials
            5.1.1 By Geography
            5.1.2 By Indication
            5.1.3 By Gene Type
            5.1.4 By Vector
            5.1.5 By Clinical Trial Phase
     5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario
     6.1 Regulatory Landscape
            6.1.1 US
            6.1.2 Canada
            6.1.3 Europe
            6.1.4 Japan
            6.1.5 China
            6.1.6 India
            6.1.7 Australia
     6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies
     7.1 Neovasculgen
     7.2 Glybera
     7.3 Gendicine, Rexin-G, Oncorine
            7.3.1 Gendicine
            7.3.2 Rexin G
            7.3.3 Oncorine

8. Global Gene Therapy Market

9. Gene Therapy Market by Application
     9.1 Oncology
     9.2 Cardiovascular Diseases
     9.3 Infectious Diseases
     9.4 Neurological Diseases
     9.5 Genetic Diseases
     9.6 Others

10. Global Gene Therapy Market Size by Geography
     10.1 North America
     10.2 Europe
     10.3 Asia
     10.4 Rest of the World (RoW)

11. Competitive Landscape
     11.1 Strategies Adopted by Various Players
            11.1.1 Strategic Collaborations
            11.1.2 Acquisitions
            11.1.3 Funding & Investments
     11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)
     12.1 Spark Therapeutics, LLC
     12.2 ViroMed Co. Ltd. dba VM BioPharma
     12.3 Advantagene Inc.
     12.4 Bluebird Bio
     12.5 Sanofi
     12.6 Vical Inc.
     12.7 Oxford BioMedica Plc
     12.8 Genethon
     12.9 UniQure N.V.
     12.10 Human Stem Cells Institute
     12.11 Shanghai Sunway Biotech Co. Ltd.
     12.12 Sibiono GeneTech Co. Ltd.